13F-HR filed by BML Capital Management, LLC
BML Capital Management, LLC filed this 13F-HR for the quarter ended 2023-03-31, filed 2023-04-14, with 31 holding rows worth $115,686,741.
- Accession
- 0001754960-23-000107
- Filer
- CIK 1616824
- Filed
- 2023-04-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2023
A holdings report, 31 entries on the cover page, a total value of $115,686,741 stated on the cover page (in dollars after the unit check, H1), rows summing to $115,686,741 with VALUE read as dollars as filed, 13F file number 028-22948. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| SPDR Bloomberg 1-3 Month T-Bill ETF | 78468R663 | SHS | 200,000 | $18,364,000 | dollars as filed | |
| iShares 0-3 Month Treasury Bond ETF | 46436E718 | SHS | 125,000 | $12,572,500 | dollars as filed | |
| TILLYS INC | 886885102 | CL A | 1,154,844 | $8,903,847 | dollars as filed | |
| ABERCROMBIE & FITCH CO CL A | 002896207 | Stock | 295,778 | $8,207,840 | dollars as filed | |
| CYTEIR THERAPEUTICS INC | 23284P103 | COMMON | 3,146,296 | $5,726,259 | dollars as filed | |
| PARDES BIOSCIENCES INC | 69945Q105 | COM | 3,986,577 | $5,262,282 | dollars as filed | |
| Adverum Biotechnologies, Inc. | 00773U108 | Common Stock | 7,067,179 | $5,069,994 | dollars as filed | |
| CLIMB BIO INC | 28658R106 | COMMON STOCK | 1,658,170 | $4,808,693 | dollars as filed | |
| ATHIRA PHARMA INC | 04746L104 | COM | 1,864,907 | $4,662,268 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 212,179 | $4,646,720 | dollars as filed | |
| SATSUMA PHARMACEUTICALS INC | 80405P107 | COM | 6,440,000 | $4,498,340 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 208,161 | $4,410,932 | dollars as filed | |
| TALARIS THERAPEUTICS INC | 87410C104 | COM | 1,929,484 | $3,627,430 | dollars as filed | |
| EMBARK TECHNOLOGY INC | 29079J202 | COM NEW | 1,285,390 | $3,611,946 | dollars as filed | |
| METACRINE INC | 59101E103 | COM | 6,167,458 | $3,519,152 | dollars as filed | |
| ORAMED PHARMACEUTICALS INC | 68403P203 | COM NEW | 1,355,925 | $2,955,917 | dollars as filed | |
| ASTROTECH CORP | 046484309 | COM | 220,410 | $2,349,571 | dollars as filed | |
| JOUNCE THERAPEUTICS INC | 481116101 | COM | 1,087,961 | $2,012,728 | dollars as filed | |
| FORTE BIOSCIENCES INC | 34962G109 | COM | 1,735,075 | $1,752,426 | dollars as filed | |
| ORUKA THERAPEUTICS INC COM | 00211Y506 | Stock | 706,930 | $1,406,791 | dollars as filed | |
| CARISMA THERAPEUTICS INC | 14216R101 | COM | 411,398 | $1,275,334 | dollars as filed | |
| RETRACTABLE TECHNOLOGIES INC | 76129W105 | COM | 668,575 | $1,170,006 | dollars as filed | |
| VERRICA PHARMACEUTICALS INC | 92511W108 | COM | 150,000 | $975,000 | dollars as filed | |
| Surrozen, Inc. | 86889P109 | COM | 1,494,037 | $899,410 | dollars as filed | |
| Milestone Pharmaceuticals Inc | 59935V107 | COM | 220,000 | $866,800 | dollars as filed | |
| LISATA THERAPEUTICS INC | 128058302 | COM | 243,839 | $791,258 | dollars as filed | |
| NEXTCURE INC | 65343E108 | COM | 306,465 | $453,568 | dollars as filed | |
| GRAPHITE BIO INC | 38870X104 | COM | 152,291 | $373,113 | dollars as filed | |
| PASSAGE BIO INC | 702712100 | COM | 337,467 | $323,192 | dollars as filed | |
| ADICET BIO INC | 007002108 | COM | 30,000 | $172,800 | dollars as filed | |
| NEOLEUKIN THERAPEUTICS INC | 64049K104 | COM | 23,749 | $16,624 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001754960-23-000107 | this filing | 2023-04-14 | acceptance time not in the bulk data set |